Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial /
Background After acute coronary syndrome, diabetes conveys an excess risk of ischaemic cardiovascular events. A reduction in mean LDL cholesterol to 1.4-1.8 mmol/L with ezetimibe or statins reduces cardiovascular events in patients with an acute coronary syndrome and diabetes. However, the efficacy...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2019
|
| Sorozat: | LANCET DIABETES & ENDOCRINOLOGY
7 No. 8 |
| Tárgyszavak: | |
| doi: | 10.1016/S2213-8587(19)30158-5 |
| mtmt: | 31072777 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/23453 |